Oyster Point Pharma Competitors

Oyster Point Pharma (NASDAQ:OYST) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Earnings and Valuation

This table compares Oyster Point Pharma and Kymera Therapeutics' gross revenue, earnings per share and valuation.

Profitability

This table compares Oyster Point Pharma and Kymera Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

70.2% of Oyster Point Pharma shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 36.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Oyster Point Pharma and Kymera Therapeutics, as reported by MarketBeat.com.

Oyster Point Pharma presently has a consensus price target of $50.00, suggesting a potential upside of 144.62%. Kymera Therapeutics has a consensus price target of $50.3333, suggesting a potential upside of 9.75%. Given Oyster Point Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Oyster Point Pharma is more favorable than Kymera Therapeutics.

Summary

Oyster Point Pharma beats Kymera Therapeutics on 4 of the 7 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Analyst Recommendations

This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Oyster Point Pharma, as provided by MarketBeat.

BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, suggesting a potential upside of 4.17%. Oyster Point Pharma has a consensus target price of $50.00, suggesting a potential upside of 144.62%. Given Oyster Point Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Oyster Point Pharma is more favorable than BioCryst Pharmaceuticals.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are held by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 36.9% of Oyster Point Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioCryst Pharmaceuticals and Oyster Point Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and Oyster Point Pharma's top-line revenue, earnings per share and valuation.

Oyster Point Pharma has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Oyster Point Pharma beats BioCryst Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

bluebird bio (NASDAQ:BLUE) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for bluebird bio and Oyster Point Pharma, as provided by MarketBeat.com.

bluebird bio presently has a consensus price target of $68.4667, indicating a potential upside of 145.05%. Oyster Point Pharma has a consensus price target of $50.00, indicating a potential upside of 144.62%. Given bluebird bio's higher probable upside, equities analysts plainly believe bluebird bio is more favorable than Oyster Point Pharma.

Volatility & Risk

bluebird bio has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Institutional and Insider Ownership

94.3% of bluebird bio shares are owned by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are owned by institutional investors. 3.6% of bluebird bio shares are owned by company insiders. Comparatively, 36.9% of Oyster Point Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares bluebird bio and Oyster Point Pharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares bluebird bio and Oyster Point Pharma's revenue, earnings per share and valuation.

Oyster Point Pharma has lower revenue, but higher earnings than bluebird bio. Oyster Point Pharma is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

bluebird bio beats Oyster Point Pharma on 7 of the 13 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Volatility and Risk

Vericel has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500.

Insider & Institutional Ownership

93.1% of Vericel shares are owned by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are owned by institutional investors. 4.3% of Vericel shares are owned by company insiders. Comparatively, 36.9% of Oyster Point Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vericel and Oyster Point Pharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vericel and Oyster Point Pharma, as provided by MarketBeat.com.

Vericel currently has a consensus price target of $49.00, indicating a potential upside of 21.26%. Oyster Point Pharma has a consensus price target of $50.00, indicating a potential upside of 144.62%. Given Oyster Point Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Oyster Point Pharma is more favorable than Vericel.

Earnings & Valuation

This table compares Vericel and Oyster Point Pharma's gross revenue, earnings per share and valuation.

Vericel has higher revenue and earnings than Oyster Point Pharma. Oyster Point Pharma is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Oyster Point Pharma on 9 of the 13 factors compared between the two stocks.

Scholar Rock (NASDAQ:SRRK) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Analyst Ratings

This is a summary of recent recommendations for Scholar Rock and Oyster Point Pharma, as provided by MarketBeat.com.

Scholar Rock currently has a consensus price target of $61.60, suggesting a potential upside of 21.74%. Oyster Point Pharma has a consensus price target of $50.00, suggesting a potential upside of 144.62%. Given Oyster Point Pharma's higher probable upside, analysts clearly believe Oyster Point Pharma is more favorable than Scholar Rock.

Insider and Institutional Ownership

61.9% of Scholar Rock shares are owned by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are owned by institutional investors. 24.6% of Scholar Rock shares are owned by insiders. Comparatively, 36.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Scholar Rock has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Earnings & Valuation

This table compares Scholar Rock and Oyster Point Pharma's top-line revenue, earnings per share and valuation.

Oyster Point Pharma has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Scholar Rock and Oyster Point Pharma's net margins, return on equity and return on assets.

Summary

Oyster Point Pharma beats Scholar Rock on 8 of the 12 factors compared between the two stocks.

Oyster Point Pharma (NASDAQ:OYST) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.

Profitability

This table compares Oyster Point Pharma and Ocugen's net margins, return on equity and return on assets.

Volatility & Risk

Oyster Point Pharma has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its share price is 256% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Oyster Point Pharma and Ocugen, as provided by MarketBeat.com.

Oyster Point Pharma currently has a consensus price target of $50.00, suggesting a potential upside of 144.62%. Ocugen has a consensus price target of $4.80, suggesting a potential downside of 46.49%. Given Oyster Point Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oyster Point Pharma is more favorable than Ocugen.

Institutional and Insider Ownership

70.2% of Oyster Point Pharma shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 36.9% of Oyster Point Pharma shares are owned by insiders. Comparatively, 3.5% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Oyster Point Pharma and Ocugen's revenue, earnings per share and valuation.

Ocugen is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Oyster Point Pharma beats Ocugen on 6 of the 11 factors compared between the two stocks.